FDA Issues Communication Regarding Giazo NDA

Salix Pharmaceuticals Wednesday announced the FDA has issued a complete response letter regarding the New Drug Application (NDA) for Giazo (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.
MarketWatch